Sat.Jul 17, 2021 - Fri.Jul 23, 2021

article thumbnail

New patent for Eisai Inc drug LENVIMA

Drug Patent Watch

Annual Drug Patent Expirations for LENVIMA Lenvima is a drug marketed by Eisai Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph…. The post New patent for Eisai Inc drug LENVIMA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

What They Said – FDA Press Releases Mid-2021

Eye on FDA

It has been a regular feature of the blog to give a read on what FDA has been talking about, at least through the form of press releases. It is not always an easy task because the nature of FDA’s practice in this respect has evolved over time. But here is what we see looking at the first 6 months 2021, and comparing it to mid-years past. You may recall from the last posting on this topic at the beginning of the year, during 2020, FDA had a lot to say – a real lot, and that isn’

FDA 93
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

All eyes on Lab Innovations 2021

Drug Discovery Today

~ UK’s biggest trade show for the laboratory industry returns for 2021 ~

article thumbnail

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

The Pharma Data

– DALVANCE® is the first and only single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

New patent for Adamas Pharma drug GOCOVRI

Drug Patent Watch

Annual Drug Patent Expirations for GOCOVRI Gocovri is a drug marketed by Adamas Pharma and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent for Adamas Pharma drug GOCOVRI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

Why is the FDA Pre-submission tool underused?

Pharmaceutical Development Group

Introduction Food and Drug Administration is a government entity in the United States whose objective is to protect the public by verifying that nutritional supplements are safe to use and accurately labelled. Businesses can even use the FDA Pre-submission to get feedback on possible and planned medical advice, biologics and medication submission. It’s a fantastic service to use, but we have noticed that it’s often overlooked.

FDA 52

More Trending

article thumbnail

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

The Pharma Data

In consultation with the U.S. Food and Drug Administration (FDA), Bristol Myers Squibb has made the difficult decision to voluntarily withdraw the indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma (HCC) who were previously treated with sorafenib from the U.S. market. We took this action following the Agency’s industry-wide evaluation of accelerated approvals for checkpoint inhibitors that have not met their post-marketing requirements demonstrating co

article thumbnail

Pharmaceutical companies with the most ‘New Combination’ drugs

Drug Patent Watch

This chart shows the companies which have received the most New Combination exclusivities in the past five years. New Combinations are one of the categories for which the FDA grants…. The post Pharmaceutical companies with the most ‘New Combination’ drugs appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Predicting Protein Structures with Deep Learning

Nvidia Developer: Drug Discovery

Solving a mystery that stumped scientists for decades, last November a group of computational biologists from Alphabet’s DeepMind used AI to predict a. Solving a mystery that stumped scientists for decades, last November a group of computational biologists from Alphabet’s DeepMind used AI to predict a protein’s structure from its amino acid sequence.

Disease 52
article thumbnail

COVID-19 Emergency Use Authorisation Approval Process of US FDA

ProRelix Research

Emergency Use Authorisation Approval Process of US FDA and Treatments Approved for COVID – 19 in the USA The COVID-19 pandemic has transformed the worldwide regulator performing on approval of […]. The post COVID-19 Emergency Use Authorisation Approval Process of US FDA appeared first on ProRelix Research.

FDA 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

The Pharma Data

Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer’s disease clinical development portfolio at the Alzheimer’s Association International Conference (AAIC), which will be held in Denver, Colorado and online July 26-30, 2021. The company’s contributions to AAIC will include several presentations highlighting data on ADUHELM (aducanumab-avwa) injection 100 mg/mL solution, which was recently granted accelerated approval by the U.S.

article thumbnail

Which pharmaceutical companies have the largest patent portfolios?

Drug Patent Watch

A strong patent portfolio is at the core of branded pharmaceutical firms. Accordingly, one way to assess the relative strength of pharmaceutical firms is to compare their patent-counts. This chart…. The post Which pharmaceutical companies have the largest patent portfolios? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Want A Great Team? Pick Great Leaders.

Dark Matter Blog

Back in 2015, I felt compelled to set out in a new direction in drug discovery. I was in my third year as VP of Chemistry for Celgene. This was a great gig – good people, good science. However, it required a level of travel that began to seem excessive. My kids were old enough to know I was missing and young enough to care. And I live in the “Hollywood” of biotech, the Boston/Cambridge area – there seems to be an exciting new biotech start-up in this neighborhood every six weeks!

RNA 52
article thumbnail

Specialty Pharmacy’s Explosive 340B Growth

Drug Channels

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017. That’s about six times faster than the overall mail and specialty market.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Antibiotics may help to treat melanoma

The Pharma Data

Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine. Researchers from KU Leuven may have found a new weapon in the fight against melanoma: antibiotics that target the ‘power plants’ of cancer cells.

article thumbnail

New patent expiration for Allergan drug AVYCAZ

Drug Patent Watch

Annual Drug Patent Expirations for AVYCAZ Avycaz is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are eight patents protecting…. The post New patent expiration for Allergan drug AVYCAZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

To the Builders Blazing our Path to Amazing Medicines

Dark Matter Blog

Arrakis has gone through many significant transitions since its founding in 2015. We’ve evolved and matured scientifically. We’ve added investors and partners. And, of course, people come and go. Today, we reach a bittersweet transition at Arrakis. We bid our head of research and employee #005, Jim Barsoum, au revoir , as he marches bravely into a well-earned retirement.

article thumbnail

Informa Connect’s Finance and Accounting for Bioscience Companies – Hybrid Events

Drug Channels

Finance and Accounting for Bioscience Companies – Hybrid Events. September 20-21, Boston MA | September 22, Virtual Experience | September 23-24, Burlingame, CA. www.informaconnect.com/financeaccountingeast. www.informaconnect.com/financeaccountingwest. Tailored to the unique nuisances of bioscience companies, these CPE-accredited annual events bring together the brightest financial and accounting minds from the nation’s leading trailblazers.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2 development for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer – – Arvinas to receive $650 million in an upfront payment, in addition to a potential $1.4 billion in milestone payments; profits and costs to be shared 50/50 worldwide – – Pfizer to complete a $350 mil

article thumbnail

New patent expiration for Otsuka drug ABILIFY

Drug Patent Watch

Annual Drug Patent Expirations for ABILIFY Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in six NDAs. It is available from two suppliers.…. The post New patent expiration for Otsuka drug ABILIFY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Brian McNamara appointed CEO Designate of new independent Consumer Healthcare company

The Pharma Data

The Board of GSK (GSK) today announces that Brian McNamara, the CEO of GSK Consumer Healthcare (a Joint Venture between GSK and Pfizer) has been appointed as CEO Designate of the new, listed Consumer Healthcare company which will result from the proposed demerger of Consumer Healthcare from GSK in 2022. As set out at GSK’s Investor Update on 23 June 2021, subject to approval from shareholders, the separation of Consumer Healthcare will be by way of a demerger in mid-2022 of at least 80% of GSK’s

article thumbnail

Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders

The Pharma Data

Data Include Phase 3 Results Showing that the Primary Endpoint of Spontaneous, Treated Annualized Bleeding Rates During Prophylaxis with Recombinant von Willebrand Factor in Adults with von Willebrand Disease, was Met 12 Abstracts Presented Across Takeda’s Hematology Portfolio and Pipeline Support Takeda’s Commitment to Improving Patient Care Today as well as Transforming Future Care.

article thumbnail

Sanofi continues streamlining of established products with sale of dental care brands to Septodont

The Pharma Data

Sanofi has concluded an agreement to divest an integrated portfolio of dental care brands and related medical devices to Septodont, a French privately-owned company headquartered near Paris. Divested portfolio includes four dental care brands Ultracain ® , Rodogyl ® , Birodogyl ® and Dontisolon ® , as well as related medical devices, mostly marketed in Europe.

article thumbnail

Teva Announces Changes to Executive Management Team

The Pharma Data

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Brendan O’Grady, Executive Vice President, North America Commercial, will leave Teva to pursue a career opportunity outside of the pharmaceutical industry, and Sven Dethlefs, who currently serves as Teva’s Executive Vice President, Global Marketing and Portfolio and International Markets Commercial has been appointed the new head of North America Commercial.

article thumbnail

Odile Bain Memorial Prize recognizes brilliant research in parasitology

The Pharma Data

Researchers in the field of parasitology celebrated for contributions early in their scientific careers Together with scientific publisher Parasites & Vector, Boehringer Ingelheim has sponsored the award since its founding in 2014 Award serves to foster career growth in parasitology as well as keep memory of parasitologist Odile Bain alive. To celebrate outstanding contributions in the field of parasitology early on in their scientific careers, Dr Goylette Chami, University of Oxford, UK, an

article thumbnail

Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

The Pharma Data

NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Disease 52
article thumbnail

Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement

The Pharma Data

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2021 financial results on Tuesday, August 3, 2021. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at [link].

Disease 52
article thumbnail

New patent for G1 Therap drug COSELA

Drug Patent Watch

Annual Drug Patent Expirations for COSELA Cosela is a drug marketed by G1 Therap and is included in one NDA. There are nine patents protecting this drug. This drug has…. The post New patent for G1 Therap drug COSELA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Which pharmaceutical drugs have the most drug patents in Austria?

Drug Patent Watch

This chart shows the drugs with the most patents in Austria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Austria? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

VALNEVA AND PFIZER COMPLETE RECRUITMENT FOR PHASE 2 TRIAL OF LYME DISEASE VACCINE CANDIDATE

The Pharma Data

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. (NYSE: PFE), today announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15.

Vaccine 52
article thumbnail

llergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting

The Pharma Data

– Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) Annual Meeting being held July 23-27 in Las Vegas, NV. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an investigational presbyopia treatment, and updated analyses on DURYSTA (bimatoprost intracameral implant), the first and only FDA-approved dissolvable

article thumbnail

Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)

The Pharma Data

PRNewswire/ — AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA ® ) in combination with azacitidine for the potential treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes (MDS) based on revised International Prognostic Scoring System (IPSS-R).

article thumbnail

Allergan Aesthetics Continues Partnership with Girls Inc. to Empower Confidence in High School-Aged Girls Interested in STEM

The Pharma Data

PRNewswire/ — Today Allergan Aesthetics, now an AbbVie company, announces its third consecutive year of partnership with Girls Inc. and debut of its Empowering Confidence Workshops , a nationwide mentoring initiative. Based on a 2020 Girls Inc. report, many girls have a hard time picturing themselves in STEM. The virtual workshops will pair mentees with female physicians to offer career guidance and developmental skills to underserved, high school-aged girls as they look to higher educati

Science 52